Your browser doesn't support javascript.
loading
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn, Friedrich; Wangen, Christina; Häge, Sigrun; Peter, Antonia Sophia; Dobler, Gerhard; Hurst, Brett; Julander, Justin; Fuchs, Jonas; Ruzsics, Zsolt; Überla, Klaus; Jäck, Hans-Martin; Ptak, Roger; Muehler, Andreas; Gröppel, Manfred; Vitt, Daniel; Peelen, Evelyn; Kohlhof, Hella; Marschall, Manfred.
Afiliação
  • Hahn F; Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.
  • Wangen C; Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.
  • Häge S; Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.
  • Peter AS; Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.
  • Dobler G; Institute of Microbiology, Bundeswehr, Neuherbergstraße 11, 80937 München, Germany.
  • Hurst B; Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA.
  • Julander J; Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA.
  • Fuchs J; Institute for Virology, University Medical Center/Universitätsklinikum Freiburg, Hermann-Herder Str 11, 79104 Freiburg, Germany.
  • Ruzsics Z; Institute for Virology, University Medical Center/Universitätsklinikum Freiburg, Hermann-Herder Str 11, 79104 Freiburg, Germany.
  • Überla K; Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.
  • Jäck HM; Division of Immunology, Department of Medicine 3, FAU, Glückstraße 6, 91054 Erlangen, Germany.
  • Ptak R; Drug Development Division, Infectious Disease Research, Southern Research, 431 Aviation Way, Frederick, MD 21701, USA.
  • Muehler A; Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany.
  • Gröppel M; Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany.
  • Vitt D; Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany.
  • Peelen E; Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany.
  • Kohlhof H; Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany.
  • Marschall M; Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.
Viruses ; 12(12)2020 12 05.
Article em En | MEDLINE | ID: mdl-33291455
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Oxirredutases atuantes sobre Doadores de Grupo CH-CH / Reposicionamento de Medicamentos / SARS-CoV-2 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Viruses Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Oxirredutases atuantes sobre Doadores de Grupo CH-CH / Reposicionamento de Medicamentos / SARS-CoV-2 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Viruses Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha